Navigation Links
Stemedica Issued U.S. Patent For Ectodermal Stem Cells
Date:4/30/2013

San Diego, CA (PRWEB) April 30, 2013

Stemedica Cell Technologies, Inc., a leading manufacturer of adult allogeneic stem cells and stem cell factors announced that the Company has been issued “keystone” Patent No. 8,420,394 titled “Culturing Ectodermal Cells Under Reduced Oxygen Tension” by the United States Patent and Trademark Office (USPTO). This patent broadly covers Stemedica’s proprietary manufacturing process for enhancing the proliferation and differentiation potential of ectodermal cells of any origin. The ectodermal layer gives rise to the cells of the skin and nervous system. The patented process provides Stemedica exclusivity for expanding and manufacturing ischemia tolerant ectodermal cells under reduced oxygen tension.

Nikolai Tankovich, MD, PhD, FASLMS, President and Chief Medical Officer of Stemedica noted, “We are pleased that the USPTO recognizes the uniqueness of the technology and processes to manufacture ectodermal cell of any origin. This includes, but is not limited to: allogeneic and autologous adult, embryonic, parthenogenic and iPS sources of stem cells. When compared to stem cells expanded in normal oxygen, Stemedica cells exhibit superior migratory and engraftment properties, enhanced gap junction formation and a unique gene profile. These critical cell characteristics are the direct result of Stemedica’s proprietary technology and expansion methodology.”

Alex Kharazi, MD, PhD, Chief Technology Officer at Stemedica noted that, “We recently published data from the spinal cord injury study in rats done by Ivan Cheng, MD, at Stanford University showing significant efficacy of Stemedica’s neural stem cells injected intrathecally both distally and at the site of injury. We also anticipate publishing extremely promising data in the application of our neural stem cells, mesenchymal stem cells and combined treatment in a mouse model of Alzheimer’s disease. This large scale animal study was funded by the Swiss government and examines both young and older mice for anatomical and biomarker changes in beta amyloid and tau proteins and brain re-perfusion.”

Maynard Howe, PhD, Vice Chairman and Chief Executive Officer of Stemedica commented, “While we are pleased to have added another patent to our growing portfolio of intellectual property, we are extremely excited to be issued this “keystone” patent. It represents the culmination of our research and development, coupled with our cGMP manufacturing processes and our license to make these cells broadly available.”

About Stemedica Cell Technologies, Inc. http://www.stemedica.com
Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke, acute myocardial infarction, and cutaneous photoaging. Stemedica is currently developing regulatory pathways for a number of medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.

For more information please contact Dave McGuigan at dmcguigan (at) stemedica (dot) com

Read the full story at http://www.prweb.com/releases/stemedica-patent/ectoderm-stem-cells/prweb10683883.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Stemedica Issued U.S. Patent For Stem Cell Treatment of Diabetic Retinopathy and Diabetic Optic Neuropathy
2. Stephen Epstein, MD To Head Scientific & Medical Advisory Board For Stemedica’s Cardiology Division
3. Emory Cardiologists Arshed Quyyumi And Javed Butler Join Stemedica Cardiology Division Scientific Advisory Board
4. Stemedica Enters into Stem Cell Licensing Agreement with Kalbe Farma
5. Enbrel® (etanercept) Patent Issued
6. Saladax Biomedical, Inc. Issued Six Patents Containing Broad Claims in the Immunoassay Space
7. 12th U.S. Patent Issued To Dyadic International
8. MiMedx Is Issued Four Additional U.S. Patents For Placental Tissue Grafts
9. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
10. Cenestra Health Announces Granting of Broad Patent Covering Proprietary Bioactive Lipid Formulations
11. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , Feb. 23, 2017 Aviva Systems ... announced the acquisition of GenWay Biotech Incorporated, a ... service and product offering for both the research ... facilitate growth and enhance capabilities for both entities. GenWay,s ... ELISA assays will nicely complement ASB,s objective to ...
(Date:2/22/2017)... Kan. , Feb. 22, 2017  Aratana Therapeutics, Inc. ... development and commercialization of innovative biopharmaceutical products for companion animals, ... 2017 at 8:30 a.m. ET to discuss financial results from ... Interested participants and investors may access the ... ...
(Date:2/22/2017)...  PrimeVax Immuno-Oncology, Inc. announced today its CEO, ... Biocom Global Life Science Partnering Conference.  The presentation will ... the Torrey Pines Lodge, in San Diego.  ... who have chosen our company, amongst numerous others, to ... and clinical researchers," said Mr. Chen. "In contrast to ...
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS ... precision treatments for neurodegenerative diseases, today announced it has issued a scientific white ... is one of a series of commentaries from ProMIS’s scientific team offering insight ...
Breaking Biology Technology:
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/8/2017)... NEW YORK , Feb. 8, 2017 /PRNewswire/ ... an individual,s voice to match it against a ... voice such as pitch, cadence, and tone are ... systems require minimal hardware installation, as most PCs ... remotely for different transactions. Voice recognition biometrics are ...
(Date:2/8/2017)... 7, 2017 Report Highlights The ... from $8.3 billion in 2016 at a compound annual ... Report Includes - An overview of the global ... with data from 2015 and 2016, and projections of ... of the market on the basis of product type, ...
Breaking Biology News(10 mins):